Curated News
By: NewsRamp Editorial Staff
September 11, 2025
Spark Biomedical Revolutionizes Women's Health with Wearable Neurostimulation Tech
TLDR
- Spark Biomedical's FDA-cleared Sparrow Ascent and upcoming OhmBody offer non-invasive neurostimulation advantages for treating opioid withdrawal and women's health conditions.
- Spark Biomedical combines trigeminal and vagus nerve stimulation through wearable devices to address brain imbalances and reduce symptoms like menstrual bleeding by 55%.
- Spark Biomedical's neurostimulation technology improves women's health and treats vulnerable newborns affected by opioid addiction, making healthcare more accessible and effective.
- Neurostimulation reduces menstrual blood loss by 55% and shortens cycles while improving mood and energy through non-invasive wearable technology.
Impact - Why it Matters
This development matters because it addresses critical gaps in women's healthcare that have been historically neglected. The wearable neurostimulation technology offers a non-invasive, drug-free alternative for managing menstrual symptoms and other women's health conditions, potentially reducing reliance on medications with side effects. For the millions of women suffering from heavy menstrual bleeding, endometriosis, PCOS, and menopause symptoms, this innovation could significantly improve quality of life. Additionally, the technology's application in treating opioid addiction and neonatal withdrawal syndrome demonstrates its potential to address broader public health crises, making advanced medical treatment more accessible and reducing healthcare costs associated with traditional interventions.
Summary
Daniel Powell, a medical device industry veteran with over 25 years of experience, is leading groundbreaking innovation in wearable neurostimulation technology through his company Spark Biomedical. As CEO and co-founder, Powell has leveraged his expertise in neuromodulation to develop the FDA-cleared Sparrow Ascent device for treating opioid withdrawal and addiction in adults, while also pioneering solutions for Neonatal Opioid Withdrawal Syndrome. His passion for using electricity to treat disease, particularly through non-invasive approaches combining trigeminal and vagus nerve stimulation, has positioned Spark at the forefront of medical technology innovation.
The company recently achieved a significant milestone by securing funding from Wellcome Leap to advance women's health innovation through its OhmBody division. This funding will enable Spark to conduct an FDA-style clinical study, the final step toward obtaining regulatory clearance for bringing their revolutionary menstrual wellness product to market. Clinical trials have demonstrated remarkable results, including a 55% reduction in blood loss and 20% shorter cycle times, along with significant reductions in cramping and improvements in energy and mood for women experiencing heavy menstrual bleeding.
Looking ahead, Spark Biomedical and its OhmBody division aim to expand their wearable neurostimulation solutions to address other critical women's health issues including endometriosis, PCOS, and menopause. The company's mission focuses on addressing the severe neglect in women's healthcare through scientifically rigorous, accessible neurostimulation technology that can make a profound impact on women's lives while navigating the complex challenges of regulatory approval, reimbursement systems, and changing medical community behaviors.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, Spark Biomedical Revolutionizes Women's Health with Wearable Neurostimulation Tech
